DK1951659T3 - Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf - Google Patents

Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf

Info

Publication number
DK1951659T3
DK1951659T3 DK06850138.6T DK06850138T DK1951659T3 DK 1951659 T3 DK1951659 T3 DK 1951659T3 DK 06850138 T DK06850138 T DK 06850138T DK 1951659 T3 DK1951659 T3 DK 1951659T3
Authority
DK
Denmark
Prior art keywords
glucagon receptor
preparation
receptor antagonists
therapeutic use
compounds
Prior art date
Application number
DK06850138.6T
Other languages
English (en)
Inventor
Mark Donald Chappell
Scott Eugene Conner
Philip Arthur Hipskind
Jason Eric Lamar
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1951659T3 publication Critical patent/DK1951659T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK06850138.6T 2005-11-18 2006-11-10 Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf DK1951659T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73797905P 2005-11-18 2005-11-18
PCT/US2006/060769 WO2007114855A2 (en) 2005-11-18 2006-11-10 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
DK1951659T3 true DK1951659T3 (da) 2010-10-11

Family

ID=38470878

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06850138.6T DK1951659T3 (da) 2005-11-18 2006-11-10 Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf

Country Status (12)

Country Link
US (1) US8076374B2 (da)
JP (1) JP5100657B2 (da)
CN (1) CN101309894B (da)
AT (1) ATE473961T1 (da)
AU (1) AU2006341392B2 (da)
BR (1) BRPI0618484A2 (da)
CA (1) CA2629321C (da)
DE (1) DE602006015509D1 (da)
DK (1) DK1951659T3 (da)
ES (1) ES2346246T3 (da)
PT (1) PT1951659E (da)
WO (1) WO2007114855A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2159221A1 (en) * 2004-06-14 2010-03-03 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
KR20160052792A (ko) 2007-02-09 2016-05-12 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
CN104803891B (zh) 2008-08-13 2017-10-20 症变治疗公司 胰高血糖素拮抗剂
JP2012504630A (ja) 2008-10-03 2012-02-23 シェーリング コーポレイション グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
EP2655331A1 (en) 2010-12-23 2013-10-30 Pfizer Inc Glucagon receptor modulators
GEP20156351B (en) * 2011-02-08 2015-08-25 Pfizer Glucagon receptor modulator
KR20140023441A (ko) 2011-07-22 2014-02-26 화이자 인코포레이티드 퀴놀린일 글루카곤 수용체 조절제
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
US10201617B2 (en) 2014-10-24 2019-02-12 Zhuhai Beihai Biotech Co., Ltd. 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
CN110143935B (zh) * 2019-06-03 2022-09-30 华侨大学 一种2，5-二取代呋喃衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
JP2005511683A (ja) 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
AU2003291959A1 (en) * 2002-12-20 2004-07-14 Novo Nordisk A/S Novel glucagon antagonists
WO2004063147A1 (en) * 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
US20080254182A1 (en) 2004-04-26 2008-10-16 Laurens Last Packaged Flowable Ice Product, Such as a Milk Shake

Also Published As

Publication number Publication date
CA2629321A1 (en) 2007-10-11
DE602006015509D1 (de) 2010-08-26
AU2006341392B2 (en) 2012-05-17
AU2006341392A1 (en) 2007-10-11
CN101309894B (zh) 2012-10-03
US8076374B2 (en) 2011-12-13
JP2009519227A (ja) 2009-05-14
JP5100657B2 (ja) 2012-12-19
WO2007114855A2 (en) 2007-10-11
WO2007114855A3 (en) 2007-11-29
BRPI0618484A2 (pt) 2011-08-30
ES2346246T3 (es) 2010-10-13
CA2629321C (en) 2013-08-06
PT1951659E (pt) 2010-09-10
US20080319074A1 (en) 2008-12-25
ATE473961T1 (de) 2010-07-15
CN101309894A (zh) 2008-11-19

Similar Documents

Publication Publication Date Title
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
DK1758853T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
DK1861360T3 (da) Pyrrolidin-derivater som histamin-H3-receptorantagonister
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung